Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer

Yoon, Seobin; Lee, Bum-Kyu; Kim, Keun Pil

doi:10.1016/j.phymed.2023.155120

Cited by 2 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, chemotherapy is still the primary treatment approach following surgical resection of colorectal cancer [ 4 ]. Irinotecan (IRT), an FDA-approved topoisomerase I inhibitor derived from the Chinese tree Camptotheca acuminate , is a first-line chemotherapeutic drug for metastatic colon or rectal carcinoma [ 5 , 6 ]. However, challenges such as side effects, multidrug resistance, low stability, and short half-life hinder its broad application.…”

Section: Introductionmentioning

confidence: 99%

Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer

Yang,

Liu,

Yang

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Colorectal cancer (CRC) ranks as the third most prevalent global malignancy, marked by significant metastasis and post-surgical recurrence, posing formidable challenges to treatment efficacy. The integration of oligonucleotides with chemotherapeutic drugs emerges as a promising strategy for synergistic CRC therapy. The nanoformulation, lipid nanoparticle (LNP), presents the capability to achieve co-delivery of oligonucleotides and chemotherapeutic drugs for cancer therapy. In this study, we constructed lipid nanoparticles, termed as LNP-I-V by microfluidics to co-deliver oligonucleotides miR159 mimics (VDX05001SI) and irinotecan (IRT), demonstrating effective treatment of CRC both in vitro and in vivo. The LNP-I-V exhibited a particle size of 118.67 ± 1.27 nm, ensuring excellent stability and targeting delivery to tumor tissues, where it was internalized and escaped from the endosome with a pH-sensitive profile. Ultimately, LNP-I-V significantly inhibited CRC growth, extended the survival of tumor-bearing mice, and displayed favorable safety profiles. Thus, LNP-I-V held promise as an innovative platform to combine gene therapy and chemotherapy for improving CRC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%